



AstraZeneca/MedImmune Immuno-Oncology Clinical Trials Backgrounder

Some of the compounds from AZ/MedImmune within this document refer to pipeline products that are still under development. AZ/MedImmune pipeline products are investigational products and as such are not approved by the US Food and Drug Administration, European Medicines Agency or any other regulatory agency for the uses under investigation. Information regarding these investigational products should under no circumstances be regarded as a recommendation for their use, safety or efficacy.

Industry-Leading Pipeline

AstraZeneca/MedImmune is committed to developing a variety of Immuno-Oncology (IO) therapies designed to reprogram the immune system so that it can recognize and attack cancer cells. Our development program includes **19 late-stage pipeline clinical trials** evaluating therapies for non-small cell lung cancer (NSCLC), bladder, head and neck squamous cell carcinoma (HNSCC), gastric, pancreatic, hepatocellular carcinoma (HCC) and blood cancers.^{1,2,3}



1 AstraZeneca. Clinical Trials Appendix Full-Year and Q4 2016 Update. 21 February 2017.

https://www.astrazeneca.com/content/dam/az/PDF/Full_year_and_q4_2016_results/Full_Year_and_Q4_2016_Results_Clinical_trials_appendix.pdf.

2 National Institutes of Health. Durvalumab+Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian). 23 February 2017. <https://clinicaltrials.gov/ct2/show/NCT03043872?term=CASPIAN&rank=1>.

3 National Institutes of Health. A Study of Durvalumab Versus Standard of Care in Advanced Non-Small Cell Lung Cancer. 23 February 2017. <https://clinicaltrials.gov/ct2/show/NCT03003962?term=durvalumab+NSCLC&rank=3>.